Viridian Therapeutics, Inc.

NASDAQ:VRDN

Biotechnology

Healthcare
$30.12 -0.88%

-$0.15 today

Market cap
$3.42B
Beta
0.90
P/E (TTM)
-4.7
EPS (TTM)
-$3.53
52W Low $13.18High $34.29

Volume 1.49M

Average 2.86M

VRDN Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Viridian Therapeutics, Inc.NASDAQ: VRDN

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation growth accelerates

Q2 FY2026 stock-based compensation of $16.98M rose 56.6% year over year, ahead of the +38.3% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 26.8% from the prior quarter. Over 3 fiscal years it compounded at +30.9% a year.

Context

  • Stock-based compensation amounted to 62.5% of revenue in FY2025, down 13894.4 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +56.6% holds above the trailing-twelve-month pace of +38.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$16.98M+26.8% QoQ
Last fiscal yearDec 2025
$44.3M+5.1% YoY
LTMJun 2026
$53.61M+38.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+56.6%——
1 year+5.1%——
3-year CAGR+30.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
44.3M USD
Year-over-year change
+5.1%
4-year CAGR
+32.3%

Stock-Based Compensation vs competitors

How VRDN compares with its peers on the latest reported figures

  • VRDN's LTM Jun 2026 stock-based compensation of $53.61M is the largest of the 4 companies compared; the peer median is $31.69M.
  • Its year-over-year change of +38.3% is the highest of 4, against a peer median of -0.5%.
  • Stock-based compensation amounts to 75.4% of revenue for VRDN, versus a peer median of 416.2%.
VRDN Competitors Peer median
Stock-Based Compensation for VRDN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VRDNViridian Therapeutics, Inc.LTM Jun 2026$53.61M +38.3%+30.9%75.4%
OCULOcular Therapeutix, Inc.LTM Mar 2026$48.31M +35.8%+36.5%92.8%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$31.69M -0.5%+25.3%416.2%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$5.14M -37.3%+4.9%1543.3%
Peer median (excluding VRDN) $31.69M-0.5%+25.3%416.2%

Competitors are the stored peer set for VRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(79.41M)(129.87M)(237.73M)(269.95M)(342.6M)
Depreciation & Amortization120K255K522K540K460K
Deferred Income Tax00000
Stock-Based Compensation14.47M19.77M67.17M42.15M44.3M
Change in Working Capital1.72M15.96M(9.43M)9.6M23.03M
Accounts Receivables(451K)349K0102K0
Inventory00000
Accounts Payables1.66M11.52M(12.04M)(73K)6.56M
Other Working Capital520K4.09M2.62M9.57M16.47M
Other Non-Cash Items8.52M54K(4.71M)(14.66M)(1.58M)
Operating Cash Flow(54.58M)(93.84M)(184.17M)(232.32M)(276.39M)
Capital Expenditures(338K)(797K)(898K)(511K)(495K)
Acquisitions (Net)00000
Purchases of Investments(188.43M)(223.26M)(407.88M)(695.07M)(579.28M)
Sales of Investments114.4M108.94M314.53M466.93M542.21M
Other Investing Activities79K0000
Investing Cash Flow(74.29M)(115.13M)(94.25M)(228.65M)(37.56M)
Debt Repayment05M15M028.88M
Common Stock Issued114.24M291.87M125.07M453.66M348.33M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(5.93M)(18.63M)9.41M(20.92M)49.54M
Financing Cash Flow125.28M322.24M225.67M457.74M426.74M
Effect of Forex Changes00000
Net Change in Cash(3.6M)113.28M(52.75M)(3.23M)112.79M
Free Cash Flow(54.92M)(94.64M)(185.07M)(232.83M)(276.89M)

Viridian Therapeutics, Inc.

NASDAQ:VRDN

Intrinsic Alpha fair value

Locked

Current Price

$30.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.